Unraveling gut microbiota in Parkinson's disease and atypical parkinsonismOriginal paper
Karen Pendergrass is a microbiome researcher specializing in microbiome-targeted interventions (MBTIs). She systematically analyzes scientific literature to identify microbial patterns, develop hypotheses, and validate interventions. As the founder of the Microbiome Signatures Database, she bridges microbiome research with clinical practice. In 2012, based on her own investigative research, she became the first documented case of FMT for Celiac Disease, four years before the first published case study.
Read MoreWhat was studied?
This study examined whether abnormalities in gut microbiota composition are associated with Parkinson's disease (PD) and atypical parkinsonism. Researchers performed 16S ribosomal RNA gene sequencing on fecal samples to characterize gut bacterial taxa across disease groups. They compared unadjusted results with confounder-adjusted analyses, accounting for factors including dietary habits, to see which microbial differences held up. The design also compared PD to two atypical parkinsonian syndromes, progressive supranuclear palsy (PSP) and multiple system atrophy (MSA), to test how their microbiota profiles relate to PD.
Who was studied?
The cohort included 350 individuals total. This comprised 193 people with idiopathic PD, of whom 39 were drug naive, stratified by disease duration, along with 22 patients with progressive supranuclear palsy (PSP), 22 patients with multiple system atrophy (MSA), and 113 healthy controls. Fecal samples from all 350 participants underwent 16S rRNA gene sequencing, and dietary habits and other confounders were recorded and adjusted for in the analysis.
What were the most important findings?
Unadjusted comparisons between PD and healthy controls showed several differences in taxa abundance, but most of these differences shrank substantially after adjusting for confounders. Lower abundance of Lachnospiraceae was the one difference that held between de novo PD and healthy controls, and it remained lower across nearly all PD duration strata. Decreased Lachnospiraceae together with increased Lactobacillaceae and Christensenellaceae was associated with a worse clinical profile, including higher frequencies of cognitive impairment, gait disturbances, and postural instability. MSA and PSP patients largely shared the microbial changes seen in PD, though MSA did not show the same reduction in Lachnospiraceae.
What are the greatest implications of this study?
The findings suggest that many previously reported gut microbiota differences in PD are confounded by factors such as diet rather than reflecting disease-specific biology. Lachnospiraceae depletion emerges as a more robust, duration-independent signal that may relate directly to PD pathophysiology rather than disease progression. The association of Lachnospiraceae, Lactobacillaceae, and Christensenellaceae shifts with clinical severity, including cognitive and motor decline, points to a possible link between specific gut taxa and disease phenotype. The overlap in microbial changes between PD and the atypical parkinsonian syndromes MSA and PSP suggests some gut microbiota alterations may reflect shared neurodegenerative processes rather than being unique to PD.